Esperion Therapeutics Inc (ESPR) Receives Average Recommendation of “Buy” from Brokerages

Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) have received a consensus recommendation of “Buy” from the sixteen research firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $77.23.

A number of equities analysts have recently weighed in on ESPR shares. Chardan Capital boosted their price objective on shares of Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a research report on Wednesday, December 6th. Needham & Company LLC raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and boosted their price objective for the company from $72.00 to $81.00 in a research report on Thursday, December 14th. UBS Group set a $88.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a research report on Wednesday, January 17th. BidaskClub raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 16th. Finally, Northland Securities reissued a “buy” rating and issued a $72.00 price objective on shares of Esperion Therapeutics in a research report on Friday, November 10th.

In related news, Director Nicole Vitullo sold 9,326 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total transaction of $502,205.10. Following the completion of the transaction, the director now owns 2,472 shares of the company’s stock, valued at $133,117.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 32.50% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Voya Investment Management LLC increased its position in Esperion Therapeutics by 12.7% during the second quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $331,000 after purchasing an additional 806 shares during the last quarter. TIAA CREF Investment Management LLC increased its position in Esperion Therapeutics by 3.0% during the second quarter. TIAA CREF Investment Management LLC now owns 39,074 shares of the biopharmaceutical company’s stock worth $1,808,000 after purchasing an additional 1,148 shares during the last quarter. Alliancebernstein L.P. increased its position in Esperion Therapeutics by 5.3% during the second quarter. Alliancebernstein L.P. now owns 30,070 shares of the biopharmaceutical company’s stock worth $1,392,000 after purchasing an additional 1,500 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in Esperion Therapeutics by 3.4% during the second quarter. Parametric Portfolio Associates LLC now owns 50,420 shares of the biopharmaceutical company’s stock worth $2,333,000 after purchasing an additional 1,658 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its position in Esperion Therapeutics by 8.3% during the third quarter. Russell Investments Group Ltd. now owns 25,072 shares of the biopharmaceutical company’s stock worth $1,257,000 after purchasing an additional 1,913 shares during the last quarter. 92.30% of the stock is owned by hedge funds and other institutional investors.

Shares of Esperion Therapeutics (ESPR) traded up $1.81 during midday trading on Friday, hitting $74.88. 428,225 shares of the company’s stock traded hands, compared to its average volume of 595,517. Esperion Therapeutics has a 12 month low of $10.82 and a 12 month high of $82.18. The stock has a market capitalization of $1,970.00, a P/E ratio of -10.92 and a beta of 2.73.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.79) by ($0.07). During the same quarter in the prior year, the firm earned ($0.77) EPS. analysts predict that Esperion Therapeutics will post -7.3 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Esperion Therapeutics Inc (ESPR) Receives Average Recommendation of “Buy” from Brokerages” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/27/esperion-therapeutics-inc-espr-receives-average-recommendation-of-buy-from-brokerages.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply